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Background:
Type A insulin resistance (IR) is caused by heterozygous mutations in the insulin receptor gene. It
presents after puberty with mild acanthosis nigricans, severe IR, and hyperandrogenism in the
absence of obesity or lipodystrophy. Treatment aims to improve insulin sensitivity and decrease
androgens. Hyperandrogenism in Type A IR likely results from insulin acting as a co-gonadotropin
directly increasing androgen synthesis in theca cells via ovarian insulin receptor signaling or
indirectly by enhancing GnRH-mediated LH release from the pituitary. Clinical hyperandrogenism
represents a serious concern for patients yet there are limited data on treatment options in severe
IR syndromes. We describe an adolescent patient with Type A IR who demonstrated resolution of
hyperandrogenism during GnRH agonist treatment while severe IR persisted. This case challenges
the notion that insulin increases steroidogenesis independently of gonadotropins.
Case description:
An adolescent female was evaluated for secondary amenorrhea and prominent hirsutism. She had a
normal BMI and laboratories revealed elevated LH to FSH ratio (LH 11.6 mIU/mL, FSH 4.2
mIU/mL), testosterone 96 ng/dL (<50), free testosterone 2.21 ng/dL (<1.09), normal glucose and
HbA1c of 5.6%. She was diagnosed with polycystic ovary syndrome (PCOS) and referred to our
Multi-Specialty Adolescent PCOS Program. There, oral glucose tolerance test (OGTT) showed
fasting glucose and insulin of 80 mg/dL and 63.1 mIU/mL, respectively. The 2-hour glucose and
insulin were 199 mg/dL and 1480 uIU/mL, respectively. Due to hyperandrogenism with severe IR,

dysglycemia and normal lipids, Type A IR was entertained. Genetic testing revealed a novel
heterozygous mutation in the insulin receptor gene (c.3095G>A(pGly1032Asp)). After standard
treatment for hirsutism and hyperinsulinism failed, the team decided to start leuprolide 11.25
mg/month intramuscular injections to improve hyperandrogenism and potentially see a secondary
benefit on insulin resistance. One month after leuprolide-induced LH suppression, dramatic
testosterone reduction and hirsutism improvement were noted (13 month follow-up, Table 1).
Repeat OGTT still showed impaired glucose tolerance and severe IR along with increased HbA1c
(17 month follow-up, Table 1). Ovarian volume had decreased substantially in both ovaries, no
longer meeting the definition of polycystic ovarian morphology (17 month follow-up, Table 1).

Conclusion:
We describe a case of an adolescent female with Type A IR whose severe hirsutism and biochemical
hyperandrogenism were successfully managed on GnRH agonist therapy, despite extreme
hyperinsulinemia. This case allowed us to examine the frequently debated bidirectional
relationship between insulin and hyperandrogenism, often deemed independent of gonadotropin
activity. It is postulated that excess insulin activates the IGF-1 receptors on the ovary leading to
testosterone production. Therefore, in the case of severe IR syndromes, we may expect
hyperandrogenism to persist even after the gonadotropin stimulus is suppressed. Contrary to this,
our case showed clinical and biochemical hyperandrogenism that responded dramatically to
leuprolide despite persistent hyperinsulinism. Our case suggests that LH is necessary to facilitate
insulin’s action on steroidogenesis even in severe IR due to a defective insulin receptor.
GnRH agonist therapy may be helpful in cases of severe IR syndromes with distressing hirsutism
when other modalities are unsuccessful.

Table 1 Clinical and Laboratory Evaluation of an Adolescent Female with a Novel Insulin Receptor Gene Mutation
12 mo
Initial
1 mo
5 mo
9 mo
13 mo
17 mo
Reference
leuprolide
Presentation follow up follow up follow up
follow up follow up
Range
initiated
Reproductive Markers
Total testosterone (ng/dL)
96
142
99
139
7
22
<50
Free testosterone (ng/dL)
2.2
3.6
2.7
3.1
0.2
<1.09
Androstenedione (ng/dL)
258
80-240
DHEA (ng/dL)
415
39-481
DHEAS (mcg/dL)
133
50-540
17-OHP (ng/dL)
178
146
20-265
LH (mIU/mL)
11.6
12.1
9.4
12.7
0.3
1.0
FSH (mIU/mL)
4.2
4.1
4.2
4.5
2.0
Ovarian Volume (cm3)
Right Ovary
5.0
10.6
4.4
10
Left Ovary
8.9
8.8
5.7
10
Mean OV
7.0
9.7
5.1
Follicle Number Per Section
Right Ovary
7
6
10
9
Left Ovary
8
19
10
9
Mean FNPS
8
13
10
Metabolic Markers
Random cortisol (mcg/dL)
4.7
HbA1c (%)
5.6
5.5
5.4
5.8
6.4
<6
OGTT 0 min glucose (mg/dL)
80
84
91
<100
OGTT 2 hr glucose (mg/dL)
199
159
181
<140
OGTT 0 min insulin (uIU/mL)
63.1
397.0
90.9
OGTT 2 hr insulin (uIU/mL)
1480
1326
1038
Abbreviations: DHEA, dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulfate; 17-OHP, 17-hydroxyprogesterone; LH, luteinizing hormone; FSH,
follicle stimulating hormone; OV, ovarian volume; FNPS, follicle number per section; HbA1C, hemoglobin A1c; OGTT, oral glucose tolerance test; mo, month.
Reference ranges are reported when available based on internal assays.

Table 1 legend:
Table 1 provides laboratory and pelvic ultrasound results for the patient at initial presentation and throughout the treatment course at
each of her follow up visits. The shaded column demonstrates the initiation of leuprolide at the patient’s 12 month follow up visit and
the following columns to the right (13 month and 17 month follow up visits) she continues on leuprolide treatment.
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